StockNews.AI
IOVA
StockNews.AI
11 days

Iovance Biotherapeutics' (IOVA) Annual Maintenance: Assurances Collide with Adverse Disclosure as Shares Plunge 44% – Hagens Berman

1. IOVA shares fell 44% after a significant revenue miss. 2. Investigation launched over possible securities law violations.

2 mins saved
Full Article

FAQ

Why Very Bearish?

A 44% drop signals a loss of investor confidence, reminiscent of past revenue misses leading to long-term declines in biotech stocks.

How important is it?

The article directly addresses a significant decline in IOVA's share price and ongoing legal investigations.

Why Short Term?

The immediate fallout from the revenue miss and investigation may lead to continued volatility in the stock price.

Related Companies

NVTABMRNCRSP
SAN FRANCISCO--(BUSINESS WIRE)--In a dramatic turn for Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), investors watched the company's shares plunge nearly 44% on May 9, 2025, after the San Carlos-based cell therapy pioneer reported a first-quarter revenue miss that sharply contradicted earlier upbeat assurances from management. Hagens Berman is now investigating whether Iovance violated U.S. securities laws and urges Iovance investors who suffered substantial losses to submit your losses now. Th.

Related News